EXPLORE THE SCIENCE
TL;DR: A 2026 medRxiv preprint tested SimulAD, an Alzheimer’s disease progression simulator, and reported that it reproduced mean amyloid-clearance results within 5% error across six major phase III anti-amyloid trials while also separating positive trials fro…
Read article
TL;DR: A 2026 study in Nature Neuroscience from Baylor College of Medicine showed that boosting Sox9, a transcription factor that regulates aging astrocytes, improved astrocytes’ ability to clear amyloid plaques in Alzheimer’s mouse models and preserved cognit…
Read article
How Lecanemab Clears Brain Amyloid: The Microglia Key TL;DR: Lecanemab, the first Alzheimer’s antibody to slow cognitive decline, works by activating immune cells called microglia through a specific immune signaling pathway, with the molecule SPP1/osteopontin…
Read article